Achieve Life Sciences, Inc.
ACHV · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | 0.00 | -0.65 | 0.00 |
| FCF Yield | -10.37% | -11.57% | -11.97% | -7.56% |
| EV / EBITDA | -6.15 | -2.92 | -7.12 | -9.81 |
| Quality | ||||
| ROIC | -33.72% | -24.33% | -60.03% | -38.09% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.78 | 0.71 | 0.86 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -24.94% | 18.21% | -20.67% | 11.41% |
| Safety | ||||
| Net Debt / EBITDA | 1.55 | 3.36 | 0.24 | 0.23 |
| Interest Coverage | -76.52 | -65.77 | -69.70 | -61.88 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |